中国科学院机构知识库网格系统: 检索

浏览/检索结果: 共6条，第1-6条

帮助

条数/页：排序方式：
	Simultaneous determination of unecritinib (TQ-B3101) and its active metabolite crizotinib in rat plasma by LC-MS/MS:An application to pharmacokinetic studies 期刊论文 OAI收割 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2024, 卷号: 246, 页码: 9 作者: Wang, Hong; Chen, Huixian; Cui, Xinran; Zhang, Yuchen; Zhou, Jialan \| 收藏 \|
	A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib 期刊论文 OAI收割 CLINICAL LUNG CANCER, 2021, 卷号: 22 作者: Chen, Kaiyan; Zhang, Fanrong; Pan, Guoqiang; Sheng, Jiamin; Ye, Junyi \| 收藏 \|
	Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3 期刊论文 OAI收割 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15 作者: Selvaggi, G. \| 收藏 \|
	SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors 期刊论文 OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 7 作者: Xia, Zong-jun; Ji, Yin-chun \| 收藏 \|
	Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met 期刊论文 OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 卷号: 8, 期号: 8, 页码: 1541-1550 作者: Wang, Lei; Gao, Mingzhao; Tong, Mengya; Xie, Chengying; He, Ye \| 收藏 \|
	Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance 期刊论文 OAI收割 ACTA PHARMACEUTICA SINICA B, 2015, 卷号: 5, 期号: 1, 页码: 34-37 作者: Song, Zilan; Wang, Meining; Zhang, Ao \| 收藏 \|